Transforming growth factor beta-2 drives trabecular meshwork progenitor cell differentiation through SMAD2/3...

Area of Science:

• Ophthalmology
• Cell Biology
• Regenerative Medicine

Background:

• Primary open-angle glaucoma (POAG) is a leading cause of irreversible blindness.
• Elevated intraocular pressure (IOP) in POAG results from impaired aqueous humor outflow through the trabecular meshwork (TM) and Schlemm's canal.
• The mechanisms behind TM tissue maintenance failure and regenerative capacity loss in POAG are not fully understood.

Purpose of the Study:

• To investigate the role of transforming growth factor beta 2 (TGFβ2) in regulating trabecular meshwork progenitor cell (TMPC) function.
• To determine if elevated TGFβ2 contributes to TM dysfunction and progenitor cell depletion in POAG.
• To elucidate the signaling pathways involved in TGFβ2-mediated effects on TMPCs.

Main Methods:

• In vitro studies using TMPCs.
• Treatment of TMPCs with TGFβ2.
• Analysis of gene expression related to TM differentiation and fibrosis.
• Assessment of progenitor cell markers.
• Inhibition of the TGFβ2-SMAD2/3 signaling pathway.

Main Results:

• TGFβ2 treatment induced a fibrotic, differentiated phenotype in TMPCs.
• TGFβ2 increased profibrotic gene expression and decreased progenitor cell markers.
• The TGFβ2-SMAD2/3 signaling pathway mediated these effects.
• Inhibition of this pathway preserved TMPC characteristics and reduced fibrotic gene induction.

Conclusions:

• TGFβ2 signaling pathways regulate TMPC fate in vitro.
• Elevated TGFβ2 may contribute to POAG pathogenesis by impairing TMPC function and promoting TM fibrosis.
• Targeting the TGFβ2-SMAD2/3 pathway could be a potential therapeutic strategy for POAG.